Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of LY3509754 in Healthy Participants
NCT04586920Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3509754 in psoriasis (8 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Oct 2020; status: terminated.
02
Drugs
LY3509754
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT04586920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586920.